Nektar Therapeutics (NKTR) 13.54 $NKTR
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Baxter Announces Positive Data for BAX 855; Competition Rife - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:40PM CST
Baxter International Inc. (BAX) recently disclosed additional efficacy and safety data from its Phase III pivotal study evaluating BAX 855 which is used to treat patients with hemophilia A.
NVO: 43.76 (+0.61), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A
PR Newswire - Wed Feb 11, 8:11AM CST
Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc. today presented additional efficacy and safety data from the Phase III pivotal study of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)] at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland.
NKTR: 13.54 (-0.14)
Baxter Presents Additional Data from Pivotal Study of BAX 855, Extended Half-Life Investigational Recombinant FVIII Based on ADVATE for Hemophilia A
Business Wire - Wed Feb 11, 8:00AM CST
Baxter International Inc. (NYSE:BAX) today presented additional efficacy and safety data from the Phase III pivotal study of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)] at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland.
BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
What The Chances Are Of BEACON's Success And What That Will Mean To Nektar
Scrying Biotech - at Seeking Alpha - Mon Feb 09, 11:56AM CST
NKTR: 13.54 (-0.14)
Andy Clark, Ph.D., Respiratory Drug Development Expert, Joins Respira Therapeutics, Inc. as V.P. and Chief Technology Officer
GlobeNewswire - Mon Feb 09, 7:06AM CST
Respira Therapeutics, Inc. (http://www.respiratherapeutics.com) announced today that Andy Clark, Ph.D. has been appointed as Vice President and Chief Technology Officer of the Company. Andy is a recognized expert in respiratory drug development, with 30+ years experience developing some of the pharmaceutical industries' most novel inhalation products; Pulmozyme(R), the first inhaled protein, Exubera(R) the first inhaled insulin, and Tobi Podhaler(R), the first inhaled dry powder antibiotic. He served as CTO of Inhale/Nektar Therapeutics, and most recently as CTO and site head at Novartis' pulmonary drug development site in San Carlos, CA. Andy has been awarded a number of the industry's top academic awards for his contributions to inhalation aerosol science and he holds multiple U.S. and foreign patents on successful inhaled pharmaceutical products.
NKTR: 13.54 (-0.14), NVS: 102.20 (-0.17)
Baxter (BAX) Beats Q4 Earnings Estimates, Sales Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 4:20PM CST
Baxter International Inc (BAX) reported fourth-quarter 2014 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 3 cents.
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
Will Baxter International (BAX) Disappoint Earnings in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 2:45PM CST
Baxter International Inc. (BAX) is set to report fourth-quarter 2014 results on Jan 29.
BAX: 70.39 (+0.31), ABBV: 58.05 (+1.00), NKTR: 13.54 (-0.14), HOLX: 30.46 (+0.21)
DEA removes naloxegol from Schedule II list
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 7:47AM CST
AZN: 69.96 (+0.20), NKTR: 13.54 (-0.14)
Technical Coverage on Pharma Stocks - Hospira, Auxilium Pharma, Medicines, SciClone Pharma, and Nektar Therapeutics
PR Newswire - Tue Jan 13, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Hospira Inc. (NYSE: HSP), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), The Medicines Company (NASDAQ: MDCO), SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, January 12, 2015, the NASDAQ Composite ended at 4,664.71, down 0.84%, the Dow Jones Industrial Average declined 0.54%, to finish the day at 17,640.84, and the S&P 500 closed at 2,028.26, down 0.81%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 812.68, down 0.07%, while the index has advanced 11.54% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 29.79 (+0.91), AUXL: 36.47 (-0.06), SCLN: 7.85 (+0.08), NKTR: 13.54 (-0.14), HSP: 87.35 (unch)
Nektar Therapeutics Up 13.5% Since SmarTrend Uptrend Call (NKTR)
Comtex SmarTrend(R) - Fri Jan 09, 9:25AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on October 28th, 2014 at $13.73. In approximately 2 months, Nektar Therapeutics has returned 13.52% as of today's recent price of $15.58.
NKTR: 13.54 (-0.14)
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
PR Newswire - Tue Jan 06, 7:30AM CST
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2015 at 11:00 a.m. Pacific time.
JPM: 59.67 (+0.10), NKTR: 13.54 (-0.14)
Can MannKind Corporation Stock Soar in 2015?
Brian Orelli, The Motley Fool - Motley Fool - Wed Dec 31, 7:45AM CST
This was pivotal year for MannKind in which it gained Food and Drug Administration approval for inhaled insulin Afrezza after multiple attempts. The biotech even signed up a stellar partner, Sanofi , to market the drug. But that will all be...
PFE: 34.64 (-0.23), SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02), NKTR: 13.54 (-0.14)
Interesting NKTR Put And Call Options For August 2015
at The Street - Wed Dec 24, 2:03PM CST
Investors in Nektar Therapeutics saw new options begin trading this week, for the August 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly...
NKTR: 13.54 (-0.14)
Baxter Seeks FDA Approval of BAX111 to Advance VWD Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:00PM CST
Baxter International Inc. (BAX) filed a BLA with the FDA for the approval of BAX 111 - an investigational drug for the treatment of patients with von Willebrand disease (VWD).
ICUI: 88.98 (+0.42), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14), OSUR: 8.13 (+0.06)
Nektar Therapeutics Has Returned 13.2% Since SmarTrend Recommendation (NKTR)
Comtex SmarTrend(R) - Mon Dec 22, 9:52AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on October 28th, 2014 at $13.73. In approximately 2 months, Nektar Therapeutics has returned 13.22% as of today's recent price of $15.54.
NKTR: 13.54 (-0.14)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 14.92 (+0.93), ACRX: 7.29 (-0.06), EGLT: 10.60 (+0.58), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14)
Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis
PR Newswire - Mon Dec 15, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Zogenix Inc. (NASDAQ: ZGNX), Eli Lilly and Company (NYSE: LLY), Nektar Therapeutics (NASDAQ: NKTR), Sanofi (NYSE: SNY), and Novartis AG (NYSE: NVS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, December 12, 2014, the NASDAQ Composite ended at 4,653.60, down 1.16%, the Dow Jones Industrial Average lost 1.79%, to finish the day at 17,280.83, and the S&P 500 closed at 2,002.33, down 1.62%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 792.98, down 1.63%, while the index has advanced 7.99% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.43 (+0.05), LLY: 70.56 (+0.03), SNY: 49.42 (+0.82), NKTR: 13.54 (-0.14), NVS: 102.20 (-0.17)
Secondary Hyperparathyroidism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x9vld/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/6x9vld/secondary
OPK: 13.80 (-0.28), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14)
Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer
PR Newswire - Thu Dec 11, 5:00PM CST
Nektar Therapeutics (NASDAQ: NKTR) today presented biomarker data from a sub-study of the Phase 3 BEACON study of etirinotecan pegol (NKTR-102) which collected and analyzed circulating tumor cell (CTC) samples from patients in the study. A total of 80% of the 852 patients enrolled in the BEACON trial participated in the CTC sub-study. Among the 627 patients who participated and had evaluable baseline samples, CTCs were detected in 97% of these samples.
NKTR: 13.54 (-0.14)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Baxter Announces Positive Data for BAX 855; Competition Rife - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:40PM CST
Baxter International Inc. (BAX) recently disclosed additional efficacy and safety data from its Phase III pivotal study evaluating BAX 855 which is used to treat patients with hemophilia A.
NVO: 43.76 (+0.61), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A
PR Newswire - Wed Feb 11, 8:11AM CST
Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc. today presented additional efficacy and safety data from the Phase III pivotal study of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)] at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland.
NKTR: 13.54 (-0.14)
Baxter Presents Additional Data from Pivotal Study of BAX 855, Extended Half-Life Investigational Recombinant FVIII Based on ADVATE for Hemophilia A
Business Wire - Wed Feb 11, 8:00AM CST
Baxter International Inc. (NYSE:BAX) today presented additional efficacy and safety data from the Phase III pivotal study of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)] at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland.
BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
What The Chances Are Of BEACON's Success And What That Will Mean To Nektar
Scrying Biotech - at Seeking Alpha - Mon Feb 09, 11:56AM CST
NKTR: 13.54 (-0.14)
Andy Clark, Ph.D., Respiratory Drug Development Expert, Joins Respira Therapeutics, Inc. as V.P. and Chief Technology Officer
GlobeNewswire - Mon Feb 09, 7:06AM CST
Respira Therapeutics, Inc. (http://www.respiratherapeutics.com) announced today that Andy Clark, Ph.D. has been appointed as Vice President and Chief Technology Officer of the Company. Andy is a recognized expert in respiratory drug development, with 30+ years experience developing some of the pharmaceutical industries' most novel inhalation products; Pulmozyme(R), the first inhaled protein, Exubera(R) the first inhaled insulin, and Tobi Podhaler(R), the first inhaled dry powder antibiotic. He served as CTO of Inhale/Nektar Therapeutics, and most recently as CTO and site head at Novartis' pulmonary drug development site in San Carlos, CA. Andy has been awarded a number of the industry's top academic awards for his contributions to inhalation aerosol science and he holds multiple U.S. and foreign patents on successful inhaled pharmaceutical products.
NKTR: 13.54 (-0.14), NVS: 102.20 (-0.17)
Baxter (BAX) Beats Q4 Earnings Estimates, Sales Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 4:20PM CST
Baxter International Inc (BAX) reported fourth-quarter 2014 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 3 cents.
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
Will Baxter International (BAX) Disappoint Earnings in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 2:45PM CST
Baxter International Inc. (BAX) is set to report fourth-quarter 2014 results on Jan 29.
BAX: 70.39 (+0.31), ABBV: 58.05 (+1.00), NKTR: 13.54 (-0.14), HOLX: 30.46 (+0.21)
DEA removes naloxegol from Schedule II list
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 7:47AM CST
AZN: 69.96 (+0.20), NKTR: 13.54 (-0.14)
Technical Coverage on Pharma Stocks - Hospira, Auxilium Pharma, Medicines, SciClone Pharma, and Nektar Therapeutics
PR Newswire - Tue Jan 13, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Hospira Inc. (NYSE: HSP), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), The Medicines Company (NASDAQ: MDCO), SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, January 12, 2015, the NASDAQ Composite ended at 4,664.71, down 0.84%, the Dow Jones Industrial Average declined 0.54%, to finish the day at 17,640.84, and the S&P 500 closed at 2,028.26, down 0.81%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 812.68, down 0.07%, while the index has advanced 11.54% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 29.79 (+0.91), AUXL: 36.47 (-0.06), SCLN: 7.85 (+0.08), NKTR: 13.54 (-0.14), HSP: 87.35 (unch)
Nektar Therapeutics Up 13.5% Since SmarTrend Uptrend Call (NKTR)
Comtex SmarTrend(R) - Fri Jan 09, 9:25AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on October 28th, 2014 at $13.73. In approximately 2 months, Nektar Therapeutics has returned 13.52% as of today's recent price of $15.58.
NKTR: 13.54 (-0.14)
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
PR Newswire - Tue Jan 06, 7:30AM CST
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2015 at 11:00 a.m. Pacific time.
JPM: 59.67 (+0.10), NKTR: 13.54 (-0.14)
Can MannKind Corporation Stock Soar in 2015?
Brian Orelli, The Motley Fool - Motley Fool - Wed Dec 31, 7:45AM CST
This was pivotal year for MannKind in which it gained Food and Drug Administration approval for inhaled insulin Afrezza after multiple attempts. The biotech even signed up a stellar partner, Sanofi , to market the drug. But that will all be...
PFE: 34.64 (-0.23), SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02), NKTR: 13.54 (-0.14)
Interesting NKTR Put And Call Options For August 2015
at The Street - Wed Dec 24, 2:03PM CST
Investors in Nektar Therapeutics saw new options begin trading this week, for the August 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly...
NKTR: 13.54 (-0.14)
Baxter Seeks FDA Approval of BAX111 to Advance VWD Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:00PM CST
Baxter International Inc. (BAX) filed a BLA with the FDA for the approval of BAX 111 - an investigational drug for the treatment of patients with von Willebrand disease (VWD).
ICUI: 88.98 (+0.42), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14), OSUR: 8.13 (+0.06)
Nektar Therapeutics Has Returned 13.2% Since SmarTrend Recommendation (NKTR)
Comtex SmarTrend(R) - Mon Dec 22, 9:52AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on October 28th, 2014 at $13.73. In approximately 2 months, Nektar Therapeutics has returned 13.22% as of today's recent price of $15.54.
NKTR: 13.54 (-0.14)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 14.92 (+0.93), ACRX: 7.29 (-0.06), EGLT: 10.60 (+0.58), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14)
Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis
PR Newswire - Mon Dec 15, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Zogenix Inc. (NASDAQ: ZGNX), Eli Lilly and Company (NYSE: LLY), Nektar Therapeutics (NASDAQ: NKTR), Sanofi (NYSE: SNY), and Novartis AG (NYSE: NVS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, December 12, 2014, the NASDAQ Composite ended at 4,653.60, down 1.16%, the Dow Jones Industrial Average lost 1.79%, to finish the day at 17,280.83, and the S&P 500 closed at 2,002.33, down 1.62%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 792.98, down 1.63%, while the index has advanced 7.99% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.43 (+0.05), LLY: 70.56 (+0.03), SNY: 49.42 (+0.82), NKTR: 13.54 (-0.14), NVS: 102.20 (-0.17)
Secondary Hyperparathyroidism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x9vld/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/6x9vld/secondary
OPK: 13.80 (-0.28), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14)
Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer
PR Newswire - Thu Dec 11, 5:00PM CST
Nektar Therapeutics (NASDAQ: NKTR) today presented biomarker data from a sub-study of the Phase 3 BEACON study of etirinotecan pegol (NKTR-102) which collected and analyzed circulating tumor cell (CTC) samples from patients in the study. A total of 80% of the 852 patients enrolled in the BEACON trial participated in the CTC sub-study. Among the 627 patients who participated and had evaluable baseline samples, CTCs were detected in 97% of these samples.
NKTR: 13.54 (-0.14)
